In 81 antiretroviral-naive HIV-1 chronic-infected patients, we found a correlation among tonsillar tissue viral load, and virological and immunological measures in blood at baseline. No correlation was observed after 1 year of antiretroviral therapy. A protease inhibitor-containing regimen was the best predictor of good tonsillar tissue virological response.
References
1.
RuizL., van LunzenJ., ArnoA., StellbrinkH.J., SchneiderC., RullM., CastellaE., OjangurenI., RichmanD.D., ClotetB., Tenner-RaczK., & RaczP.Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS1999; 13: F1–F8.
2.
LafeuilladeA., CholletL., HittingerG., ProfiziN., CostesO., & PoggiC.Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. Journal of Infectious Diseases1998; 177: 235–238.
3.
MartinezE., ArnedoM., GinerV., GilC., CaballeroM., AlosL., GarciaF., HoltzerC., MallolasJ., MiroJ.M., PumarolaT., & GatellJ.M.Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS2001; 15: 1477–1482.
4.
PlanaM., GarciaF., GallartT., TortajadaC., SorianoA., PalouE., MalenoM.J., BarceloJ.J., VidalC., CrucetaA., MiroJ.M., & GatellJ.M.Immunological benefits of antiretroviral therapy in very early stages of asymtomatic chronic HIV-1 infection. AIDS2000; 14: 1921–1933.
5.
SchackerT.W., NguyenP.L., MartinezE., ReillyC., GatellJ.M., HorbanA., BakowskaE., BerzinsB., van LeeuwenR., WolinskyS., HaaseA.T., & MurphyR.L.Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. Journal of Infectious Diseases2002; 186: 1092–1097.
6.
GunthardH.F., HavlirD.V., FiscusS., ZhangZ.Q., EronJ., MellorsJ., GulickR., FrostS.D., BrownA.J., SchleifW., ValentineF., JonasL., MeibohmA., IgnacioC.C., IsaacsR., GamagamiR., EminiE., HaaseA., RichmanD.D., & WongJ.K.Residual human immunodeficiency (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. Journal of Infectious Diseases2001; 183: 1318–1327.
7.
GarciaF., RomeuJ., GrauI., SambeatM.A., DalmauD., KnobelH., Gomez-SirventJ.L., ArrizabalagaJ., CrucetaA., ClotetB.G., PodzamczerD., PumarolaT., GallartT., O'BrienW.A., MiroJ.M., & GatellJ.M.A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS1999; 13: 2377–2388.
8.
PantaleoG., CohenO.J., SchackerT., VaccarezzaM., GraziosiC., RizzardiG.P., KahnJ., FoxC.H., SchnittmanS.M., SchwartzD.H., CoreyL., & FauciA.S.Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nature Medicine1998; 4: 341–345.
9.
RizzardiG.P., De BoerR.J., HooverS., TambussiG., ChapuisA., HalkicN., BartP.A., MillerV., StaszewskiS., NotermansD.W., PerrinL., FoxC.H., LangeJ.M., LazzarinA., & PantaleoG.Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. Journal of Clinical Investigation2000; 105: 777–782.
